Sendek Joel 4
4 · Spero Therapeutics, Inc. · Filed Dec 15, 2017
Insider Transaction Report
Form 4
Sendek Joel
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2017-12-13+27,795→ 27,795 totalExercise: $11.63Exp: 2027-12-12→ Common Stock (27,795 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.